Choose Your Country or Region

Pralsetinib (BLU-667)

Name: Pralsetinib (BLU-667)
Brand: Selleck Chemicals
SKU: S8716
Rating: 5 (3 reviews)

Catalog No.S8716 Synonyms: CS 3009, Gavreto

For research use only.

Pralsetinib (BLU-667, CS 3009, Gavreto) is a highly potent and selective RET (c-RET) inhibitor with an IC50 of 0.4 nM for WT RET. It also demonstrates potent activity (IC50 0.4 nmol/L) against common oncogenic RET alterations, including RET (M918T).

Pralsetinib (BLU-667) Chemical Structure

CAS No. 2097132-94-8

Selleck's Pralsetinib (BLU-667) has been cited by 3 Publications

Purity & Quality Control

Choose Selective c-RET Inhibitors

Related Compound Libraries

Other c-RET Products

Erlotinib (OSI-774)^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428)^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Pexidartinib (PLX3397)^New

Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit (c-Kit), and FLT3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Pexidartinib (PLX3397) induces apoptosis and necrosis with antitumor activity. Phase 3.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.
Erlotinib (OSI-774) HCl

Erlotinib (OSI-774, CP358774, NSC 718781) HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Crizotinib (PF-02341066)

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Sunitinib (SU11248) malate

Sunitinib (SU11248) malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

Download Inhibitor Catalog

c-RET Signaling Pathway Map

Biological Activity

Description

Targets

RET V804L ^[1] (Cell-free assay )	WT RET ^[1] (Cell-free assay)	RET V804M ^[1] (Cell-free assay)	RET M918T ^[1] (Cell-free asssay)	CCDC6-RET ^[1] (Cell-free assay)	Click to View More Targets
0.3 nM	0.4 nM	0.4 nM	0.4 nM	0.4 nM	Click to View More Targets

In vitro

BLU-667 is at least 100-fold more selective for RET over 96% of kinases tested (a panel of 371 kinases). BLU-667 specifically abrogates RET signaling in RET-altered cancers from diverse lineages. RET pathway inhibition with BLU-667 also more potently inhibits proliferation of RET-altered cell lines relative to multikinase inhibitors^[1].

In vivo

In vivo, BLU-667 potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2. BLU-667 is well tolerated throughout the in vivo studies^[1].

Protocol (from reference)

Kinase Assay: ^[1]	Human Kinase Selectivity: BLU-667 is screened at 300 nmol/L for inhibitory activity across a panel of 371 kinases. The 23 kinases inhibited >50% at 300 nmol/L are selected for full 10 point concentration-response curves with BLU-667 (1 μmol/L maximum concentration) at 200 μmol/L ATP to generate biochemical IC50 (Reaction Biology Corp) using 33P-ATP (10 mCi/mL) to initiate the reaction, followed by the detection of kinase activity by a filter-binding method.
Cell Research: ^[1]	Cell lines: LC2/ad cells,　MZ-CRC-1 cells and TT cells Concentrations: 0-1 μM Incubation Time: 90 minutes Method: --
Animal Research: ^[1]	Animal Models: PDX tumor models (BALB/c nude mice) Dosages: 3, 10, or 30 mg/kg twice daily or 60 mg/kg once daily Administration: --

References

[1] Subbiah V, et al. Cancer Discov. 2018, 8(7):836-849.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	533.60
Formula	C₂₇H₃₂FN₉O₂
CAS No.	2097132-94-8
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04760288	Not yet recruiting	Drug: Pralsetinib\|Drug: Cabozantinib\|Drug: Vandetanib	Thyroid Cancer	Hoffmann-La Roche	July 1 2022	Phase 3
NCT04697446	Enrolling by invitation	--	RET-fusion Non Small Cell Lung Cancer\|Lung Neoplasm\|Carcinoma Non-Small-Cell Lung\|Respiratory Tract Neoplasms\|Thoracic Neoplasms\|Neoplasms by Site\|Neoplasms\|Lung Diseases\|Respiratory Tract Diseases\|Carcinoma Bronchogenic\|Bronchial Diseases\|Head and Neck Neoplasms\|Carcinoma\|Neoplasms by Histologic Type\|Neoplasms Germ Cell and Embryonal\|Neoplasms Nerve Tissue\|Metastatic Non Small Cell Lung Cancer	Blueprint Medicines Corporation\|Analysis Group Inc.	December 1 2020	--
NCT03037385	Active not recruiting	Drug: pralsetinib (BLU-667)	RET-altered Non Small Cell Lung Cancer\|Medullary Thyroid Cancer\|RET-altered Papillary Thyroid Cancer\|RET-altered Colon Cancer\|RET-altered Solid Tumors\|Lung Neoplasm\|Carcinoma Non-Small-Cell Lung\|Thyroid Diseases\|Thyroid Neoplasm\|Thyroid Cancer Papillary\|Carcinoma Neuroendocrine\|Respiratory Tract Neoplasms\|Thoracic Neoplasms\|Neoplasms by Site\|Neoplasms\|Lung Diseases\|Respiratory Tract Disease\|Carcinoma Bronchogenic\|Bronchial Neoplasms\|Endocrine System Diseases\|Endocrine Gland Neoplasm\|Head and Neck Neoplasms\|Adenocarcinoma Papillary\|Adenocarcinoma\|Carcinoma\|Neoplasms Glandular and Epithelial\|Neoplasms by Histologic Type\|Neuroendocrine Tumors\|Neuroectodermal Tumors\|Neoplasms Germ Cell and Embryonal\|Neoplasms Nerve Tissue\|Colonic Neoplasms\|Colorectal Neoplasms\|Intestinal Neoplasms\|Gastrointestinal Neoplasms\|Digestive System Neoplasm\|Digestive System Disease\|Gastrointestinal Disease\|Colonic Diseases\|Intestinal Disease	Hoffmann-La Roche	March 17 2017	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):